Compare LION & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LION | GLPG |
|---|---|---|
| Founded | 1997 | 1999 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.1B |
| IPO Year | N/A | 2005 |
| Metric | LION | GLPG |
|---|---|---|
| Price | $9.18 | $33.04 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 10 | 4 |
| Target Price | $9.11 | ★ $31.33 |
| AVG Volume (30 Days) | ★ 2.9M | 86.8K |
| Earning Date | 02-05-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,858,000,000.00 | $336,643,201.00 |
| Revenue This Year | N/A | $1.76 |
| Revenue Next Year | $22.30 | $0.49 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 21.18 | 10.31 |
| 52 Week Low | $5.55 | $22.36 |
| 52 Week High | $9.25 | $37.78 |
| Indicator | LION | GLPG |
|---|---|---|
| Relative Strength Index (RSI) | 76.84 | 62.59 |
| Support Level | $8.21 | $30.73 |
| Resistance Level | $9.25 | $33.23 |
| Average True Range (ATR) | 0.43 | 0.59 |
| MACD | 0.09 | 0.18 |
| Stochastic Oscillator | 92.52 | 91.22 |
Lionsgate Studios Corp is a motion picture and television studio operations aligned with the STARZ premium subscription platform to bring a varied portfolio of entertainment to consumers around the world. The group has two reportable business segments: the Motion Picture and Television Production reportable segments. Motion Picture consists of the development and production of feature films, the acquisition of North American and world-wide distribution rights. Television Production consists of the development, production, and world-wide distribution of television productions, including television series, television movies and mini-series, and non-fiction programming.
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.